Source comparison
TB-500 Metabolism Research: Comparison of Tissue Response
Dermal Wounds High (dense capillary network) 55% faster closure vs control Angiogenesis + cell migration + MMP upregulation 2.5 mg twice daily, 10–14 days Strongest evidence base—TB-500 excels where blood supply supports cellular activity Skeletal Muscle High
This comparison does not assign a generated winner or score.
- Dermal Wounds
- High (dense capillary network)
- 55% faster closure vs control
- Angiogenesis + cell migration + MMP upregulation
- 2.5 mg twice daily, 10–14 days
- Strongest evidence base—TB-500 excels where blood supply supports cellular activity
- Skeletal Muscle
- High (rich microvascular supply)
- 38% increase in fiber regeneration
- Satellite cell activation + angiogenesis
- 4 mg twice daily, 14–21 days
- Solid response, particularly in acute injury models—less clear in chronic degeneration
- Cardiac Tissue (post-MI)
- Moderate (regional ischemia)
- 42% reduction in infarct size
- VEGF-mediated neovascularization
- 6 mg once daily, 7 days
- Promising preclinical data—mechanism targets ischemic injury directly
- Tendons
- Low (sparse vascular supply)
- 18% improvement in tensile strength
- Collagen remodeling (minimal angiogenic contribution)
- 2–4 mg twice daily, 21–28 days
- Modest benefit—actin mechanism functions but limited by avascular environment
- Articular Cartilage
- None (avascular)
- 0–5% improvement in structural properties
- Chondrocyte proliferation only
- 3 mg twice daily, 21 days
- Negligible effect—mechanism requires vascular support TB-500 can't provide here